Serum 25(OH)D and Type 2 Diabetes Association in a General Population

A prospective study

LISE LOTTE N. HUSEMOEN, PHD1
BETINA H. THUENSEN, PHD3
MOGENS FENGER, DSMC2,1,3
TORBEN JØRGENSEN, DSMC2,1,3
CHARLOTTE GLÜMER, PHD

JANNET SVENSSON, PHD4
LARS OVESEN, MD7
DANIEL R. WITTE, PHD6
ALLAN LINNEBERG, PHD6

OBJECTIVE—This study aimed to examine vitamin D status as a determinant for development of type 2 diabetes and deterioration of glucose homeostasis.

RESEARCH DESIGN AND METHODS—A random sample of the general population of Copenhagen, Denmark, was taken as part of the Inter99 study. Included were 6,405 men and women aged 30–65 years at baseline (1999–2001), with 4,296 participating in the follow-up examination 5 years later (2004–2006). Vitamin D was determined at baseline as serum 25-hydroxyvitamin D [25(OH)D]. Diabetes was defined based on an oral glucose tolerance test and a glycosylated hemoglobin (HbA1c) test. Secondary outcomes included continuous markers of glucose homeostasis.

RESULTS—The risk of incident diabetes associated with a 10 nmol/L increase in 25(OH)D was odds ratio (OR) 0.91 (95% CI 0.84–0.97) in crude analyses. The association became statistically nonsignificant after adjustment for confounders, with an OR per 10 nmol/L of 0.94 (0.86–1.03). Low 25(OH)D status was significantly associated with unfavorable longitudinal changes in continuous markers of glucose homeostasis after adjustment for confounders. Fasting and 2-h glucose and insulin as well as the degree of insulin resistance increased significantly more during follow-up among those with low 25(OH)D levels compared with those with higher levels.

CONCLUSIONS—Low 25(OH)D status was not significantly associated with incident diabetes after adjustment for confounders. However, it was significantly associated with unfavorable longitudinal changes in continuous markers of glucose homeostasis, indicating that low vitamin D status could be related to deterioration of glucose homeostasis.

Vitamin D is vital to calcium homeostasis. Deficiency may lead to bone-deforming disease in children and development of osteoporosis and osteomalacia in adults. In addition, low vitamin D status has recently been proposed as a risk factor for common chronic diseases, such as cancer, cardiovascular disease (CVD), autoimmune diseases, asthma, and allergy (1). The many roles of vitamin D are supported by the widespread distribution of the vitamin D receptor in >36 cell types, including pancreatic β-cells, skeletal muscle, and adipose tissue (2).

For most people, the main source of vitamin D is synthesis in the skin after exposure to sunlight (1). Consequently, during the winter, inhabitants of countries at latitudes above 40°N (e.g., Denmark, 56°N) cannot produce sufficient vitamin D. Thus, low vitamin D status is likely to be prevalent in Denmark and has been found in a general population sample (3).

Vitamin D deficiency has been linked to increased risk of type 2 diabetes, but the available epidemiological evidence is limited because most studies are cross-sectional (4). The few prospective studies measure dietary intake of vitamin D, which does not account for the large proportion of vitamin D produced in the skin, or they ascertain diabetes by self-report or medication registry data, which may result in misclassification of undiagnosed individuals and individuals who treat their disease with dietary changes only (5–11). The aim of this study was to examine the association between serum 25-hydroxyvitamin D (25(OH)D) status and the risk of incident type 2 diabetes and longitudinal changes in markers of glucose homeostasis in a large prospective study of the general population.

RESEARCH DESIGN AND METHODS

Study population
We used data from the Inter99 study, a population-based randomized controlled trial (CT00289237, ClinicalTrials.gov) on residents (N = 61,301) in the southern part of former Copenhagen County, which is investigating the effects of lifestyle intervention (smoking cessation, increased physical activity, and healthier dietary habits) on CVD (12). The study population was drawn from the Danish Civil Registration System and prerrandomized into four groups: 1) high-intensity intervention group (n = 11,708 invited), 2) low-intensity intervention group (n = 1,308 invited), 3) control group receiving questionnaires (n = 5,264 invited), and 4) control group followed only in central registries (n = 43,021). Subjects in groups 1 and 2 were invited to participate in a health examination in 1999–2001 and included in the current observational study. The health examination included self-administered questionnaires, a physical examination, a 2-h oral glucose tolerance test (OGTT), and various blood tests, as well as a lifestyle assessment.
Serum 25(OH)D and type 2 diabetes

consultation with personal health advice. Furthermore, participants at high risk of ischemic heart disease were included for lifestyle intervention (60%). Group 1 was offered lifestyle counseling in groups on smoking cessation and physical activity/diet during 6-month periods, and group 2 was referred to their general practitioner (12).

More specifically, groups 1 and 2 consisted of an age- and sex-stratified random sample of 13,016 men and women aged 30–65 years with 12,934 eligible for invitation. The baseline participation rate was 52.5% (n = 6,784). Participation at baseline was associated with obesity, nonsmoking, and fewer admissions for ischemic heart disease, CVD, and diabetes (12). After 5 years (median: 5.5; range: 5.0–6.0) of follow-up, all participants were invited in 2004–2006 to a reexamination with essentially the same questionnaires and examinations, with 4,513 participating. Nonparticipation at follow-up was associated with the following baseline characteristics: female sex, younger age, a less healthful lifestyle, and a less favorable risk factor profile, including lower 25(OH)D levels and higher diabetes prevalence. Only participants with a northern European origin (Denmark, Norway, Sweden, Iceland, and Faroe Islands) were included (n = 6,405 at baseline; n = 4,296 at follow-up). Prior informed written consent was obtained from all participants. The study was approved by the ethical committees of Copenhagen (KA 98155) and was in accordance with Helsinki Declaration II principles.

Diabetes and markers of glucose homeostasis

Both at baseline and follow-up, all participants without a history of diabetes underwent a 2-h standardized 75-g OGTT in the morning after an overnight fast. Plasma glucose and serum insulin were measured at 0, 30, and 120 min. Glucose concentrations were analyzed by the hexokinase/glucose-6-phosphate dehydrogenase assay (Boehringer, Mannheim, Germany). Insulin levels were measured by a fluoroimmunoassay technique (Dako Diagnostics Ltd., Cambridgeshire, U.K.). Diabetes was diagnosed based on OGTT results as fasting plasma glucose ≥7.0 or 2-h plasma glucose ≥11.1 mmol/L (13). Hemoglobin A1c (HbA1c) also was measured for all participants for a definition of diabetes as HbA1c ≥6.5% (14). Prevalent diabetes at baseline was defined as having diabetes according to OGTT criteria, HbA1c criteria, a known history of diabetes, and/or use of diabetes medication. Incident diabetes was defined as diabetes at follow-up among those without diabetes at baseline according to the criteria given above.

Insulin resistance and pancreatic \( \beta \)-cell function were estimated using both the widely used homeostasis model assessment (HOMA), which is based on fasting glucose and insulin levels only (15), and the BIGTT (\( \beta \)-Cell Function, Insulin Sensitivity, and Glucose Tolerance Test) (16), which is based on serum insulin and plasma glucose for the entire OGTT at 0, 30, and 120 min, as well as BMI and sex. Thus, HOMA gives estimates of basal insulin secretion (HOMA-%B) and hepatic insulin resistance (HOMA-IR). The BIGTT model, on the other hand, gives estimates of the acute glucose-stimulated insulin response (BIGTT-AIR) and stimulated insulin resistance (BIGTT-IR) that reflect both hepatic and muscle insulin resistance.

Vitamin D

Fasting blood was collected beginning with initial examinations in 1999, and serum samples were stored at −20°C until analysis in 2009. Vitamin D status was measured at baseline as serum 25(OH)D by high-performance liquid chromatography. The assay was standardized using the DEQUAS external standard. Stability of 25(OH)D in serum samples under different conditions has been demonstrated, so we assumed our measurements were unaffected by storage time (17). The detection limit was 10 nmol/L, and observations below this limit were assigned 10 nmol/L (n = 74). 25(OH)D was categorized into <25, ≥25–50, ≥50–75, and ≥75 nmol/L.

Self-administered questionnaire

For physical activity during leisure time, participants scored themselves as mostly sedentary, moderate activity, regular exercise, or heavy training. Smoking status was never, ex-smoker, or current smoker at <15 g/day, ≥15–25 g/day, or ≥25 g/day. On the basis of responses to qualitative questions about intake of fruit, vegetables, fish, and saturated fat, a dietary quality score was calculated (18). The average amount and type of alcoholic beverages per week during the past 12 months was used to estimate a total alcohol consumption of 0, 1–7, >7–14, >14–21, or >21 standard drinks (1.5 cl or 12 g ethanol) per week. Social class was defined based on questions regarding years of vocational training and employment status and was categorized into five classes. Family history of diabetes was defined as having a first-degree relative with diabetes. An extensive food frequency questionnaire provided information on total energy intake and specific nutrients (19). No information on supplement use was available. Drug information included insulin and other diabetes medications. Self-reported changes in dietary habits, physical activity, smoking status, and alcohol consumption were recorded at follow-up.

Physical examinations

Height and weight were measured wearing light clothes and no shoes. BMI was calculated as weight divided by height squared and categorized as underweight (<18.5 kg/m\(^2\)), normal (18.5–25 kg/m\(^2\)), overweight (≥25–30 kg/m\(^2\)), or obese (≥30 kg/m\(^2\)). Changes in weight during follow-up were calculated by subtraction and categorized as increased, unchanged, or decreased.

Statistical analyses

Data were considered observational. Statistics were performed with SAS, version 9.1 (SAS Institute Inc, Cary, NC). All reported P values are two-tailed, and statistical significance was defined as \( P < 0.05 \). Crude and adjusted associations were evaluated in a series of linear and logistic regression models. Effects from logistic regression models were reported as odds ratios (OR) with 95% CIs. Continuous outcome measures were log transformed to achieve normal distributions. \( \beta \)-coefficients from linear regression models with log-transformed outcomes were back transformed and reported as percent with 95% CI. To adjust for regression to the mean and allow effect estimates to be interpreted as outcome changes from baseline to follow-up, linear regression models with outcomes measured at follow-up were adjusted for the baseline value of the outcome. Continuous 25(OH)D was tested for linear associations by including the squared term of 25(OH)D in the models. Statistical interaction effects were evaluated by including a product term between 25(OH)D and relevant covariates. F tests and Wald tests for single parameters were used to determine significance in regression analyses. The number of participants included in the analyses differed since complete case analyses were performed and not all.
participants had complete information on all variables examined.

RESULTS—The baseline study population was 48.4% (n = 3,099) men and 51.6% (n = 3,306) women with a mean age of 46.3 years (range: 29.7–61.3). The median 25(OH)D concentration was 48.0 nmol/L, and percentiles 2.5–97.5 were 12.0–118.0 nmol/L.

25(OH)D levels strongly correlated to the season in which blood was collected, whereas dietary vitamin D intake showed only a weak and nonsignificant association with circulating 25(OH)D (Table 1). Furthermore, male sex, current smoking, low physical activity, less healthful dietary habits, obesity, low social class, and prevalent diabetes were associated with lower 25(OH)D concentrations in crude analyses (Table 1). No association with 25(OH)D concentration was observed for age, alcohol intake, total energy intake, or family history of diabetes.

The prevalence of diabetes at baseline was 10.6% (n = 677). During follow-up, 3.6% (n = 141) of participants without diabetes at baseline developed diabetes.

Low 25(OH)D status was significantly associated with a higher prevalence of diabetes at baseline both in crude analyses and after adjustment for confounders (Supplementary Table A1). Low 25(OH)D status also was significantly associated with a higher risk of incident diabetes in crude analyses (Table 2). However, the association became statistically nonsignificant after adjustment for confounders. The degree of insulin resistance as assessed by the HOMA-IR and BIGTT-IR indexes increased significantly more during follow-up among those with low 25(OH)D levels compared with those with higher levels. In addition, low 25(OH)D status was significantly associated with an increase in fasting and 2-h glucose as well as in fasting and 2-h insulin during follow-up. No association was observed with HbA1c, or with surrogate measures of pancreatic β-cell function (Table 3).

CONCLUSIONS—Low 25(OH)D status was not significantly associated with incident diabetes after adjustment for confounders. However, it was significantly associated with unfavorable longitudinal changes in continuous outcome variables adjusted for confounders. The degree of insulin resistance as assessed by the HOMA-IR and BIGTT-IR indexes increased significantly more during follow-up among those with low 25(OH)D levels compared with those with higher levels. In addition, low 25(OH)D status was significantly associated with an increase in fasting and 2-h glucose as well as in fasting and 2-h insulin during follow-up. No association was observed with HbA1c, or with surrogate measures of pancreatic β-cell function (Table 3).

Table 1—Baseline characteristics of the study population by 25(OH)D status

| Characteristic                          | All (N = 6,405)† | 25(OH)D <50 nmol/L (52.2%, n = 3,207) | 25(OH)D ≥50 nmol/L (47.8%, n = 2,939) | P value‡ |
|----------------------------------------|-----------------|---------------------------------------|---------------------------------------|----------|
| Men                                    | 48.4 (3,099)    | 50.5 (1,620)                          | 47.2 (1,386)                          | 0.009    |
| Current smoker                         | 35.7 (2,274)    | 38.5 (1,229)                          | 32.5 (950)                            | <0.001   |
| Mainly sedentary physical activity     | 20.7 (1,300)    | 22.4 (705)                            | 18.6 (538)                            | <0.001   |
| Less healthful dietary habits           | 16.0 (990)      | 16.7 (518)                            | 15.0 (428)                            | 0.03     |
| Low social class (class 1+2)           | 10.8 (639)      | 11.5 (340)                            | 9.8 (267)                             | 0.09     |
| Family history of diabetes             | 17.9 (1,143)    | 18.3 (588)                            | 17.5 (514)                            | 0.39     |
| Blood collection in January to March   | 21.7 (1,388)    | 29.4 (942)                            | 13.6 (400)                            | <0.001   |
| Diabetes                               | 10.6 (677)      | 12.3 (394)                            | 8.6 (253)                             | <0.001   |
| Age (years), mean (SD)                 | 46.26 (7.91)    | 46.37 (7.85)                          | 46.12 (7.99)                          | 0.40     |
| BMI (kg/m²), mean (SD)                 | 26.31 (4.65)    | 26.65 (4.90)                          | 25.87 (4.17)                          | <0.001   |
| Alcohol (drinks/week), mean (SD)       | 10.46 (13.37)   | 10.55 (13.62)                         | 10.44 (13.19)                         | 0.45     |
| Total energy intake (kJ/day), mean (SD)| 9,764.13 (3,415.10) | 9,780.03 (3,312.44) | 9,765.70 (3,463.01) | 0.59     |
| Dietary vitamin D intake (μg/day), mean (SD) | 3.60 (2.42)   | 3.58 (2.35)                           | 3.65 (2.49)                           | 0.98     |

Data are % (n) unless otherwise indicated. †Ntotal may differ because of missing values. ‡P value for differences between 25(OH)D groups below and above 50 nmol/L were tested by χ² test and Kruskal-Wallis test.

care.diabetesjournals.org
diabetes as well as markers of adverse glucose homeostasis in many, although not all, studies (4, 20). The major drawback of these studies is the potential for reverse causation (i.e., diabetes or its early determinants causing low vitamin D status rather than vice versa). Moreover, many studies do not adjust for important confounders. Previous prospective studies are inconsistent. The Nurses’ Health Study and Women’s Health Study both reported association of low supplemental and dietary vitamin D intake with increased incident diabetes risk (5, 11), whereas no association was observed in a Japanese cohort (8). However, those studies are limited by self-reports of dietary vitamin D intake, which do not consider the large proportion of vitamin D produced in the skin. A prospective study based on the Framingham Offspring cohort associates a predicted 25(OH)D score with incident type 2 diabetes (21). However, that study is limited because 25(OH)D was not actually measured.

Four studies previously examined the prospective association of serum 25(OH)D and diabetes incidence (6, 7, 9, 10). One used pooled data from two Finnish cohorts, the Finnish Mobile Clinic Health Examination Survey and the Mini-Finland Health Survey, and finds an inverse association in men, but not in women (6).

Table 2—Multiple logistic regression analyses of the prospective association between baseline 25(OH)D status and 5-year diabetes incidence

| 25(OH)D status (nmol/L) | Diabetes incidence % (n/n_total)† | Risk of incident diabetes, OR (95% CI) |
|-------------------------|----------------------------------|-------------------------------------|
|                         |                                  | Crude                               |
| <25                     | 4.6 (22/477)                     | 1.96 (1.02–3.78)                    |
| ≥25–50                  | 4.2 (60/1,415)                   | 1.80 (1.03–3.15)                    |
| ≥50–75                  | 2.9 (35/1,201)                   | 1.22 (0.67–2.22)                    |
| ≥75                     | 2.4 (16/666)                     | 1.00 (reference)                    |
| F_trend Value           | 0.008                            |                                     |
| Per 10 nmol/L increase  | 0.91 (0.84–0.97)                 | 0.93 (0.86–1.00)                    |
| P value                 | 0.006                            | 0.059                               |

†Incident diabetes at follow-up was defined as having diabetes according to OGTT criteria, HbA1c criteria, a known history of diabetes, and/or use of diabetes medication among those without diabetes at baseline. §Models were adjusted for (1) season of blood collection, sex, age, family history of diabetes, BMI, and change in weight during follow-up; (2) plus leisure time physical activity, dietary habits, alcohol consumption, smoking status, total energy intake, and social class; (3) plus randomization group and self-reported changes in dietary habits, physical activity, smoking status, and alcohol consumption during follow-up.

Table 3—Multiple linear regression analyses of association between baseline serum 25(OH)D and longitudinal changes in continuous markers of glucose homeostasis during 5 years of follow-up

| Outcome           | Change in outcome during follow-up in % per 10 nmol/L increase in baseline | P value |
|-------------------|--------------------------------------------------------------------------|--------|
| HbA1c             | −0.04 (−0.09 to 0.02)                                                    | 0.18    |
| HOMA-IR           | −0.91 (−1.57 to −0.24)                                                   | 0.008   |
| BIGTT-IR          | −1.04 (−1.57 to −0.50)                                                   | <0.001  |
| HOMA-%B           | 0.21 (−0.37 to 0.80)                                                     | 0.47    |
| BIGTT-AIR         | −0.27 (−0.19 to −0.72)                                                   | 0.25    |
| Fasting glucose   | −0.20 (−0.41 to −0.19)                                                   | <0.001  |
| 2-h glucose       | −0.80 (−1.14 to −0.46)                                                   | <0.001  |
| Fasting insulin   | −0.63 (−1.24 to 0.01)                                                    | 0.045   |
| 2-h insulin       | −1.66 (−2.36 to −0.97)                                                   | <0.001  |

β-coefficients from linear regression models were back transformed and reported as percent because of log transformation of the outcome variables. Regression models with outcomes measured at follow-up were adjusted for baseline outcome values to adjust for regression to the mean and to allow effect estimates to be interpreted as outcome changes from baseline to follow-up. Regression models were adjusted for sex, age, BMI, season of blood collection, leisure time physical activity, dietary habits, alcohol consumption, smoking status, total energy intake, social class, family history of diabetes, randomization group, change in weight, and self-reported changes in dietary habits, physical activity, smoking status, and alcohol consumption during follow-up. Subjects with a known history of diabetes did not undergo an OGTT and, therefore, were not included in the analyses.

A major limitation of the study is the ascertainment of diabetes from registry data of patients receiving reimbursements for type 2 diabetes medication, resulting in misclassification of undiagnosed individuals or those treated with dietary changes only. The second study also used registry data and finds a significant inverse association between 25(OH)D and incidence of diabetes (9). That study had a relatively short follow-up time (average 1.3 years) and was restricted to patients with measured 25(OH)D. The third study was nested within the Nurses’ Health Study and, thus, restricted to women; it finds that higher levels of plasma 25(OH)D were associated with lower risk of self-reported incident type 2 diabetes (7). In contrast, a fourth study restricted to older women does not find an association of 25(OH)D with self-reported diabetes in a post hoc analysis of three nested case-control studies within the Women’s Health Initiative Clinical Trials and Observational Study (10).

Finally, in agreement with our results, a previous study reports that baseline serum 25(OH)D was predictive of future continuous distribution of glycemic status and insulin resistance in a nondiabetic population after 10 years of follow-up. That study lacked statistical power to examine clinical outcomes and was restricted by sample size to quantitative traits (22). Results from randomized trials of the effect of vitamin D supplementation on glucose homeostasis are inconsistent, but several studies had other primary end points and, therefore, were underpowered for our outcomes of interest (23–25). In addition, many of the studies were performed in patients with diabetes. As yet, no randomized intervention trials specifically designed to
test the effect of vitamin D supplementation on incident diabetes in healthy individuals have been published. However, one study reports no effect of a relatively low dose (400 IU) of vitamin D supplementation on incident diabetes after 7 years of follow-up, in post hoc analysis (24).

The mechanism by which vitamin D deficiency and type 2 diabetes may be related is not well understood. Experimental evidence from animal and in vitro studies suggests that vitamin D may preserve glucose tolerance through effects on insulin secretion and sensitivity. These effects may be caused by effects on intracellular calcium, regulation of insulin receptor expression in peripheral tissues, or increased resilience of β-cells to the systemic inflammation seen in type 2 diabetes (23).

In conclusion, low 25(OH)D status was not significantly associated with incident diabetes after adjustment for confounders. However, it was significantly associated with unfavorable longitudinal changes in continuous markers of glucose homeostasis, indicating that low vitamin D status could be related to deterioration of glucose homeostasis. This study emphasizes the need for randomized intervention trials specifically designed to assess whether vitamin D supplementation effectively decreases the risk of developing diabetes in high-risk individuals.

Acknowledgments — This study was supported by grants from the Danish Agency for Science Technology and Innovation, the Health Insurance Foundation, the Region H Research Foundation, the Novo Nordisk Foundation, and the A.P. Møller Foundation for the Advancement of Medical Science.

Funders had no role in study design, collection, analysis, or data interpretation and no influence in the writing of the manuscript or the decision to submit the manuscript for publication. The researchers are independent from funders.

L.L.N.H., B.H.T., M.F., T.J., L.O., and A.L. declare that they have no relationships with any companies that might have an interest in the submitted work in the previous 3 years.

L.N.H. contributed to development of the hypothesis and study design, was responsible for the statistical analyses, wrote the first draft of the manuscript, and coordinated the completion of the manuscript. B.H.T. and M.F. were responsible for the measurement of vitamin D, contributed to the interpretation of results, and revised the manuscript. T.J. contributed to the development of the hypothesis and study design, was the principal investigator of the Inter99 study and responsible for data collection, contributed to the interpretation of results, and revised the manuscript. L.O. provided expertise within the field of diabetes, contributed to the interpretation of results, and revised the manuscript. A.L. contributed to development of the hypothesis and study design, was responsible for the statistical analyses, contributed to the interpretation of results, and revised the manuscript. All authors approved the final version of the manuscript.

L.L.N.H. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Parts of this study were presented in abstract form at the World Congress of Epidemiology, Edinburgh, Scotland, 7–11 August 2011; the EuroPrevent Conference, Dublin, Ireland, 3–5 May 2012; and the 2nd International Vitamin Conference, Copenhagen, Denmark, 23–25 May 2012.

The authors thank the participants of the Inter99 study, the steering committee (T.J. principal investigator, Knut Borch-Johnsen, University of Southern Denmark, co-principal investigator; and Charlotta Pisinger, Research Centre for Prevention and Health), and all members of the Inter99 staff at the Research Centre for Prevention and Health and Steno Diabetes Center. The authors also thank Jette Nymann, Department of Clinical Biochemistry, Hvidovre Hospital, for the determination of serum 25(OH)D. Chris Tachibana, freelance writer, assisted with scientific editing, funded by the Capital Region of Denmark.

References
1. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266–281
2. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 2008;88:491S–499S
3. Thuesen B, Husemoen L, Fenger M, et al. Determinants of vitamin D status in a general population of Danish adults. Bone 2012;50:603–610
4. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007;92:2017–2029
5. Pittas AG, Dawson-Hughes B, Li T, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006;29:650–656
6. Knekt P, Laaksonen M, Mattila C, et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology 2008;19:666–671
7. Pittas AG, Sun Q, Manson JE, Dawson-Hughes B, Hu FB. Plasma 25-hydroxyvitamin D concentration and risk of incident type 2 diabetes in women. Diabetes Care 2010;33:2021–2023
8. Kiri K, Mizoue T, Iso H, et al.; Japan Public Health Center-based Prospective Study Group. Calcium, vitamin D and dairy intake in relation to type 2 diabetes risk in a Japanese cohort. Diabetologia 2009;52:2542–2550
9. Anderson JL, May HT, Horne BD, et al.; Intermountain Heart Collaborative (IHC) Study Group. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 2010;106:963–968
10. Robinson JG, Manson JE, Larson J, et al. Lack of association between 25(OH)D levels and incident type 2 diabetes in older women. Diabetes Care 2011;34:628–634
11. Liu S, Song Y, Ford ES, Manson JE, Buring JE, Ridker PM. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care 2005;28:2926–2932
12. Jørgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glümer C, Pisinger C. A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil 2003;10:377–386
13. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation, Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999
14. World Health Organization. Use of Glycated Hemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. Geneva, World Health Org., 2011
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419
16. Hanssen T, Drivsholm T, Urhammer SA, et al. The BIGTT test: a novel test for simultaneous measurement of pancreatic beta-cell function, insulin sensitivity, and
glucose tolerance. Diabetes Care 2007;30:257–262
17. Ockè MC, Schrijver J, Obermann-de Boer GL, Bloemberg BP, Haenen GR, Kromhout D. Stability of blood (pro)vitamins during four years of storage at −20 degrees C: consequences for epidemiologic research. J Clin Epidemiol 1995;48:1077–1085
18. Toft U, Kristoffersen LH, Lau C, Borch-Johnsen K, Jørgensen T. The Dietary Quality Score: validation and association with cardiovascular risk factors: the Inter99 study. Eur J Clin Nutr 2007;61:270–278
19. Lau C, Færch K, Glümer C, et al. Evaluation of dietary intake in a Danish population: the Inter99 study. Scand J Nutr 2004;48:136–143
20. Kositsawat J, Freeman VL, Gerber BS, Geraci S. Association of A1C levels with vitamin D status in U.S. adults: data from the National Health and Nutrition Examination Survey. Diabetes Care 2010;33:1236–1238
21. Liu E, Meigs JB, Pittas AG, et al. Predicted 25-hydroxyvitamin D score and incident type 2 diabetes in the Framingham Offspring Study. Am J Clin Nutr 2010;91:1627–1633
22. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxyvitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes 2008;57:2619–2625
23. Alvarez JA, Ashraf A. Role of vitamin d in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol 2010;2010:351385
24. de Boer IH, Tinker LF, Connelly S, et al.; Women’s Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women’s Health Initiative. Diabetes Care 2008;31:701–707
25. Pittas AG, Chung M, Trikalinos T, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med 2010;152:307–314